Molecular Biology of Pancreatic Cancer: How Useful Is It in Clinical Practice?

  • George H Sakorafas Fourth Department of Surgery, Athens University, Medical School, Attikon University Hospital. Athens, Greece
  • Vasileios Smyrniotis Fourth Department of Surgery, Athens University, Medical School, Attikon University Hospital. Athens, Greece
Keywords: Diagnosis, General Surgery, Immunotherapy, Neoplasms, Pancreas, Pancreatectomy, Population Surveillance, Prognosis, Therapeutics

Abstract

Context During the recent two decades dramatic advances of molecular biology allowed an in-depth understanding of pancreatic carcinogenesis. It is currently accepted that pancreatic cancer has a genetic component. The real challenge is now how these impressive advances could be used in clinical practice. Objective To critically present currently available data regarding clinical application of molecular biology in pancreatic cancer. Methods Reports about clinical implications of molecular biology in patients with pancreatic cancer were retrieved from PubMed. These reports were selected on the basis of their clinical relevance, and the data of their publication (preferentially within the last 5 years). Emphasis was placed on reports investigating diagnostic, prognostic, and therapeutic implications. Results Molecular biology can be used to identify individuals at high-risk for pancreatic cancer development. Intensive surveillance is indicated in these patients to detect pancreatic neoplasia ideally at a preinvasive stage, when curative resection is still possible. Molecular biology can also be used in the diagnosis of pancreatic cancer, with molecular analysis on samples of biologic material, such as serum or plasma, duodenal fluid or preferentially pure pancreatic juice, pancreatic cells or tissue, and stools. Molecular indices have also prognostic significance. Finally, molecular biology may have therapeutic implications by using various therapeutic approaches, such as antiangiogenic factors, purine synthesis inhibitors, matrix metalloproteinase inhibitors, factors modulating tumor-stroma interaction, inactivation of the hedgehog pathway, gene therapy, oncolytic viral therapy, immunotherapy (both passive as well as active) etc. Conclusion Molecular biology may have important clinical implications in patients with pancreatic cancer and represents one of the most active areas on cancer research. Hopefully clinical applications of molecular biology in pancreatic cancer will expand in the future, improving the effectiveness of treatment and prognosis of patients with pancreatic cancer.

 

Downloads

Download data is not yet available.

Author Biography

George H Sakorafas, Fourth Department of Surgery, Athens University, Medical School, Attikon University Hospital. Athens, Greece
Assistant Professor of Surgery, 4th Department of Surgery, Athens University, Medical School

References

Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-49.

Neoptolemos JP, Dunn JA, Stocken DD, et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer. A randomized controlled trial. Lancet 358:1576–85.

Orr RK. Outcomes in pancreatic cancer surgery. Surg Clin North Am 2010; 90: 219 – 234.

Abbruzzese JL. New applications of gemcitabine and future directions in the management of pancreatic cancer. Cancer 2002; 95:941–5.

Sakorafas GH, Pappa I, Smyrniotis V. Pancreatic cancer: molecular genetics and clinical applications. Encyclopedia of Life Sciences 2010; Edition] [In Press].

Maitra A, Kern SE, Hruban RH. Molecular pathogenesis of pancreatic cancer. Best Pract Res Clin Gastroenterol 2006; 20: 211 – 226.

Vitone LJ, Greenhalf W, McFaul CD, Neoptolemos JP. The inherited genetics of pancreatic cancer and prospects for secondary screening. Best Pract Res Clin Gastroenterol 2006; 20:253 – 283.

Lynch HT, Smyrk T, Kern SE et al. Familial pancreatic cancer: a review. Semin Oncol 1996; 23: 251–275.

Silverman DT, Schiffman M, Everhart J et al. Diabetes mellitus, other medical conditions and familial history of cancer as risk factors for pancreatic cancer. Br J Cancer 1999; 80: 1830–1837.

Bartsch DK. Familial pancreatic cancer. Br J Surg 2003; 90: 386–387.

Tersmette AC, Petersen GM, Offerhaus GJ et al. Increased risk of incident pancreatic cancer among first-degree relatives of patients with familial pancreatic cancer. Clin Cancer Res 2001; 7: 738–744.

Murphy KM, Brune KA, Griffin CA et al. Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%. Cancer Res 2002; 62: 3789–3793.

Greer J, Whitcomb D. Role of BRCA 1 and BRCA 2 mutations in pancreatic cancer. Gut 2007; 56: 601–5.

Goggins M, Canto M, Hruban R. Can we screen high-risk individuals to detect early pancreatic carcinoma? J Surg Oncol 2000; 74: 243 – 248.

Canto MI, Goggins M, Yeo CJ et al. Screening for pancreatic neoplasia in high-risk individuals: an EUS- based approach. Clin Gastroenterol Hepatol 2004; 2[7]: 606–621.

Shi C, Klein AP, Goggins M, et al. Increased. prevalence of precursor lesions in familial pancreatic cancer patients. Clin Cancer Res 2009; 15: 7737 – 7743

Canto MI. Screening and surveillance approaches in familial pancreatic cancer. Gastrointestinal Endosc Clin N Am 2008; 18: 535 – 553.

Harinck F, Canto MI, Schulick R, et al. Surveillance in individuals at high risk of pancreatic cancer: too early to tell? Gut 2010; 59: 1006 – 1007

Sakorafas G, Smyrniotis V, Lombardo KMR, Sarr MG. Primary pancreatic cystic neoplasms revisited. Part II. Mucinous cystic neoplasms. Surg Oncol [In Press]

Sakorafas G, Smyrniotis V, Lombardo KMR, Sarr MG. Primary pancreatic cystic neoplasms revisited. Part III. Intraductal Papillary Mucinous Neoplasms. Surg Oncol [In Press]

Ishikawa O, Ohigashi H, Imaoka S et al. Minute carcinoma of the pancreas measuring 1 cm or less in diameter—collective review of Japanese case reports. Hepatogastroenterology 1999; 46: 8–15.

Yan L, McFaul C, Howes N et al. Molecular analysis to detect pancreatic ductal adenocarcinoma in high-risk groups. Gastroenterology 2005; 128: 2124–2130.

Sakorafas GH, Tsiotou AG, Tsiotos GG. Molecular biology of pancreatic cancer: oncogenes, tumor suppressor genes, growth factors and their receptors from a clinical perspective. Cancer Treat Rev 2000; 26: 29-52.

Sakorafas GH, Tsiotos GG. Molecular biology of pancreatic cancer; potential clinical implications. BioDrugs 2001; 15: 439 – 452.

Howes N, Greenhalf W & Neoptolemos J. Screening for early pancreatic ductal adenocarcinoma in hereditary pancreatitis. Med Clin North Am 2000; 84: 719–738.

Sakorafas GH, Tsiotou AG. Pancreatic cancer in patients with chronic pancreatitis: a challenge from a surgical perspective. Cancer Treat Rev 1999; 25: 207 – 217.

Argani P, Iacobuzio-Donahue CA, Ryu B et al. Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression [SAGE]. Clin Cancer Res 2001; 7[12]: 3862–3868.

Klump B, Hsieh CJ, Nehls Oet al. Methylation status of p14ARF and p16INK4a as detected in pancreatic secretions. Br J Cancer 2003; 88: 217–222.

Yamaguchi Y, Watanabe H, Yrdiran S et al. Detection of mutations of p53 tumor suppressor gene in pancreatic juice and its application to diagnosis of patients with pancreatic cancer: comparison with K-ras mutation. Clin Cancer Res 1999; 5: 1147–1153.

Uehara H, Nakaizumi A, Tatsuta M, et al. Diagnosis of pancreatic cancer by detecting telomerase activity in pancreatic juice: comparison with K-ras mutations. Am J Gastroenterol 1999; 94: 2513–19.

Wilentz RE, Su GH, Dai JL et al. Immunohistochemical labeling for Dpc4 mirrors genetic status in pancreatic adenocarcinomas: a new marker of DPC4 inactivation. Am J Pathol 2000; 156: 37–43.

Yamamoto H, Itoh F, Nakamura H et al. Genetic and clinical features of human pancreatic ductal adenocarcinomas with widespread microsatellite instability. Cancer Res 2001; 61[7]: 3139–3144.

Nakata B,Wang YQ, Yashiro M et al. Prognostic value of microsatellite instability in resectable pancreatic cancer. Clin Cancer Res 2002; 8[8]: 2536–2540.

Sakorafas GH, Farnell MB, Farley DR, et al. Long-term results after surgery for chronic pancreatitis. Int J Pancreatol 2000; 27: 131 – 142.

Sakorafas GH, Farmell MB, Nagorney DM, et al. Pancreatoduodenectomy for chronic pancreatitis: long-term results in 105 patients. Arch Surg 2000; 135: 517 – 523.

Stapleton GN, Williamson RC. Proximal pancreatoduodenectomy for chronic pancreatitis. Br J Surg 1996; 83: 1433 – 1440.

MacKenzie MJ. Molecular therapy in pancreatic adenocarcinoma. Lancet Oncol 2004;5[9]:541–9.

Longo R, Cacciamani F, Naso G, Gasparini G. Pancreatic cancer: from molecular signature to target therapy. Critical Rev Oncol Hematol 2008; 68: 197 – 211.

Oliveira-Cunha M, Siriwardena AK, Byers R. Molecular diagnosis in pancreatic cancer. Diagn Histopathol 2008; 14: 214 – 222.

Tascilar M, Skinner H, Rosty C, et al. The SMAD4 protein and prognosis of pancreatic ductal adenocarcinoma. Clin Cancer Res 2001; 7: 4115.

Welsh J, Sapinoso L, Kern S, et al. Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum. Proc Natl Acad Sci USA 2003; 100: 3410–15.

Couch FJ, Johnson MR, Rabe K et al. Germ line Fanconi anemia complementation group C mutations and pancreatic cancer. Cancer Res 2005; 65[2]: 383–386.

van der Heijden MS, Yeo CJ, Hruban RH & Kern SE. Fanconi anemia gene mutations in young-onset pancreatic cancer. Cancer Res 2003; 63[10]: 2585–2588.

Wong HH, Lemoine NR. Pancreatic cancer: molecular pathogenesis and new therapeutic targets. Nat Rev Gastroenterol Hepatol 2009; 6: 412 – 422.

Wallace JA, et al. Sorafenib [S] plus gemcitabine [G] for advanced pancreatic cancer [PC]: A phase II trial of the University of Chicago Phase II Consortium [Abstract]. J Clin. Oncol 2007;25:a4608.

Moore MJ, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25:1960–1966.

Philip PA, et al. Phase III study of gemcitabine [G] plus cetuximab [C] versus gemcitabine in patients [pts] with locally advanced or metastatic pancreatic adenocarcinoma [PC]: SWOG S0205 study [Abstract]. J. Clin. Oncol 2007;25:a4509.

Bramhall SR, Schulz J, Nemunaitis J, Brown PD, Baillet M, Buckels JA. A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer 2002;87:161–7.

Iacobuzio-Donahue CA, Ryu B, Hruban RH & Kern SE. Exploring the host desmoplastic response to pancreatic carcinoma: gene expression of stromal and neoplastic cells at the site of primary invasion. Am J Pathol 2002; 160[1]: 91–99.

Thayer SP, di Magliano MP, Heiser PWet al. Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature 2003; 425[6960]: 851–856.

Wong HH, Lemoine NR. Biologic approaches to therapy of pancreatic cancer. Pancreatology 2008; 8: 431 – 461.

Nakamura M, Wada K, Suzuki H, et al. Long-term outcome of immunotherapy for patients with refractory pancreatic cancer. Anticancer Res 2009; 29: 831 – 836.

Abou-Alfa GK, Chapman PB, Feilchenfeldt J, et al. Targeting mutated K-ras in pancreatic adenocarcinoma using an adjuvant vaccine. Am J Clin Oncol 2010, Aug 3. [PMID:20686403].

Attikon University Hospital. Athens, Greece
Published
2012-07-10
How to Cite
Sakorafas, G., & Smyrniotis, V. (2012). Molecular Biology of Pancreatic Cancer: How Useful Is It in Clinical Practice?. JOP. Journal of the Pancreas, 13(4), 332-337. https://doi.org/10.6092/1590-8577/841